Belzutifan/MK-6482 in PNET + PPGL + VHL
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
CLINICALTRIALS.GOV IDENTIFIER: NCT04924075
DRUG/TREATMENT: Oral Treatment: Belzutifan
SPONSOR: Merck Sharp & Dohme LLC
Dr. Hendifar Discusses Belzutifan in PNET + PPGL + VHL
Merck is sponsoring a phase 2 trial for those with pheochromocytoma/paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) who have progressed in the past 12 months. Those with pNET must have experienced disease progression on or after at least 1 line of prior systemic therapy that includes an approved targeted agent such as everolimus or sunitinib. Belzutifan is a daily, oral medication currently approved for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma.
Merck Sharp & Dohme LLC
This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.